Vygon Group and Medovate have teamed up to sign an exclusive deal to distribute SAFIRA (SAFer Injection for Regional Anaesthesia) across 60 countries.
SAFIRA was developed in collaboration with Britain's NHS clinicians and makes it possible for anaesthetists to conduct a Peripheral Nerve Blockade single handedly. The technology also improves patient safety by reducing the risk of nerve damage and preventing injection at high pressures. In addition, the technology has been found to help generate significant time and cost savings to medical organisations.
The announcement follows recommendations from the European Society for Regional Anaesthesia (ESRA), which states that regional anaesthetic should be considered whenever surgery is planned for COVID-19 patients. Compared to general anaesthesia, regional preserves respiratory function and reduces the chance of transmission of COVID-19. SAFIRA claims to help hospitals meet these recommendations by making regional anaesthesia a single person procedure.
Vygon is set to begin a phased launch of the technology at the end of 2020, beginning in Europe. Commenting on the news, John Kerridge, Vice President of the Anaesthesia & Emergency Business Unit at Vygon, said: "This is a very exciting partnership for Vygon. The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions."
Stuart Thomson, Medovate MD, added that the company hopes SAFIRA will increase its recognition of the firm around the globe. "This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US and a number of other markets," he said. "This will help establish Medovate on the world stage."